Invivyd, Inc.
IVVDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 5, 2024 | Guggenheim | Evan Wang | $9.00(+151%) | $3.58 | TheFly |
| Mar 26, 2024 | Morgan Stanley | Maxwell Skor | $10.00(+210%) | $3.23 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| BTIG | maintain | Buy | Sep 14, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Aug 27, 2026 |
| BTIG | maintain | Buy | Jul 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 15, 2026 |
| BTIG | maintain | Buy | Jun 9, 2026 |
| BTIG | maintain | Buy | Jun 1, 2026 |
| BTIG | maintain | Buy | May 18, 2026 |
| BTIG | maintain | Buy | Feb 26, 2026 |
| BTIG | maintain | Buy | Dec 23, 2025 |
| D. Boral Capital | downgrade | Buy →Hold | Nov 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 31, 2025 |
| D. Boral Capital | maintain | Buy | Oct 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2025 |
| D. Boral Capital | maintain | Buy | Aug 25, 2025 |
| D. Boral Capital | maintain | Buy | Aug 19, 2025 |
| D. Boral Capital | maintain | Buy | Aug 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 26, 2025 |
| D. Boral Capital | maintain | Buy | Jun 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 28, 2025 |
| D. Boral Capital | maintain | Buy | May 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 26, 2025 |
| D. Boral Capital | maintain | Buy | Mar 20, 2025 |
| D. Boral Capital | maintain | Buy | Mar 5, 2025 |
| D. Boral Capital | maintain | Buy | Feb 24, 2025 |
Earnings History
Next report: Apr 1, 2027 · EPS est. $-0.12| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.14 | $-0.11 | $14.3M | $14.4M |
| May 14, 2026 | $-0.13 | $-0.08 | $13.7M | $18.0M |
| Mar 5, 2026 | $0.02 | $-0.06 | $17.2M | $17.2M |
| Nov 6, 2025 | $-0.06 | $-0.05 | $13.1M | $15.5M |
| Aug 14, 2025 | $-0.12 | $-0.04 | $11.8M | $29.0M |
| May 15, 2025 | $-0.14 | $-0.04 | $11.3M | $17.5M |
| Mar 20, 2025 | $-0.15 | $-0.25 | $13.8M | $34.5M |
| Nov 14, 2024 | $-0.51 | $-0.33 | $9.3M | $13.9M |
News
NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles Invivyd is scaling up production toward clinical development in 2027 There are currently no FDA approved treatments for measles, leaving a major gap in the publi…
NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome (PVS), also known as COVID vaccine injury.
Invivyd (NASDAQ: IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration. The company said LIBERTY met its safety and tolerability objectives, showing a statistically significant advantage for VYD2311
NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration.
Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine COMIRNATY® (mRNA-based COVID-19 vaccine, COVID-19 mRNA vaccine, or COVID vaccine), and (3) …
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.
NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:
BlackRock Inc. bought a new stake in shares of Invivyd, Inc. (NASDAQ: IVVD) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,134,885 shares of the company's stock, valued at approximately $14,076,000. BlackRock Inc. owned approximately 5.48% of
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the company has appointed Marc Elia, current Chairman of the Invivyd Board of Directors, as Chief Executive Officer (CEO) of the company. He will serve as Chairman and CEO of Invivyd going forward.
Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.12 per share a year ago.
NEW HAVEN, Conn., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the second quarter ended June 30, 2026, and recent business highlights.